Free Trial
NASDAQ:COGT

Cogent Biosciences (COGT) Stock Price, News & Analysis

Cogent Biosciences logo
$7.84 +0.04 (+0.51%)
(As of 12/20/2024 05:51 PM ET)

About Cogent Biosciences Stock (NASDAQ:COGT)

Key Stats

Today's Range
$7.68
$8.06
50-Day Range
$7.64
$12.30
52-Week Range
$4.28
$12.61
Volume
2.67 million shs
Average Volume
1.46 million shs
Market Capitalization
$866.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.83
Consensus Rating
Moderate Buy

Company Overview

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Cogent Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
39th Percentile Overall Score

COGT MarketRank™: 

Cogent Biosciences scored higher than 39% of companies evaluated by MarketBeat, and ranked 712th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cogent Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cogent Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Cogent Biosciences are expected to grow in the coming year, from ($2.42) to ($2.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cogent Biosciences is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cogent Biosciences is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cogent Biosciences has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.62% of the outstanding shares of Cogent Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Cogent Biosciences has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Cogent Biosciences has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cogent Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cogent Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.62% of the outstanding shares of Cogent Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Cogent Biosciences has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Cogent Biosciences has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cogent Biosciences has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Cogent Biosciences this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for COGT on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
Receive COGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

COGT Stock News Headlines

HC Wainwright Has Negative Forecast for COGT FY2024 Earnings
Buy this coin BEFORE Inauguration Day …
Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.
See More Headlines

COGT Stock Analysis - Frequently Asked Questions

Cogent Biosciences' stock was trading at $5.88 at the beginning of 2024. Since then, COGT stock has increased by 33.3% and is now trading at $7.84.
View the best growth stocks for 2024 here
.

Cogent Biosciences, Inc. (NASDAQ:COGT) issued its quarterly earnings results on Tuesday, November, 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.07.

Cogent Biosciences' top institutional investors include FMR LLC (7.60%), Redmile Group LLC (4.10%), State Street Corp (2.95%) and Geode Capital Management LLC (2.08%).
View institutional ownership trends
.

Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Visa (V), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/12/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COGT
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.83
High Stock Price Target
$21.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+89.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-192,410,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.30 per share

Miscellaneous

Free Float
103,923,000
Market Cap
$866.02 million
Optionable
Optionable
Beta
1.70
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:COGT) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners